klabax 250 mg/5 ml
terapia sa - romania - clarithromycinum - gran. pt. susp. orala - 250mg/5ml - macrolide, lincosamide si streptogramine macrolide
fromilid uno 500 mg comprimate cu eliberare prelungită
krka d.d., novo mesto - clarithromycinum - comprimate cu eliberare prelungită - 500 mg
klacid 125 mg/5 ml granule pentru suspensie orală
abbott laboratories gmbh - clarithromycinum - granule pentru suspensie orală - 125 mg/5 ml
klacid 250 mg/5 ml granule pentru suspensie orală
abbott laboratories gmbh - clarithromycinum - granule pentru suspensie orală - 250 mg/5 ml
brukinsa
beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - agenți antineoplazici - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).
fromilid 125 mg/5 ml granule pentru suspensie orală
krka d.d., novo mesto - clarithromycinum - granule pentru suspensie orală - 125 mg/5 ml
sunlenca
gilead sciences ireland unlimited company - lenacapavir sodium - infecții cu hiv - antivirale pentru uz sistemic - sunlenca injection, in combination with other antiretroviral(s), is indicated for the treatment of adults with multidrug resistant hiv 1 infection for whom it is otherwise not possible to construct a suppressive anti viral regimen (see sections 4. 2 și 5. sunlenca tablet, in combination with other antiretroviral(s), is indicated for the treatment of adults with multidrug resistant hiv 1 infection for whom it is otherwise not possible to construct a suppressive anti viral regimen, for oral loading prior to administration of long-acting lenacapavir injection (see sections 4. 2 și 5.
vanflyta
daiichi sankyo europe gmbh - quizartinib dihydrochloride - leucemie mieloidă - antineoplastic agents, protein kinase inhibitors - vanflyta is indicated in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by vanflyta single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (aml) that is flt3-itd positive.
claritromicin grindeks 250 mg comprimate filmate
grindeks sa - clarithromycinum - comprimate filmate - 250 mg
claritromicin grindeks 500 mg comprimate filmate
grindeks sa - clarithromycinum - comprimate filmate - 500 mg